In a recent report from the Infectious Disease Working Party of the EBMT, cidofovir was shown to be effective in both primary and secondary pre-emptive therapy. In that study, 10/20 patients with CMV disease responded to cidofovir, as did 25/38 (66%) who had failed to respond to or relapsed after pre-emptive therapy with other agents; furthermore, 62% of patients receiving and secondary pre-emptive therapy. The study showed that 10/20 patients had a complete virus clearance was obtained in half of responders. No renal toxicity developed, unlike in the retrospective EBMT analysis (25.6% of cases, being persistent in 51.7%); however, in this series, most patients had received previously, or concomitantly with cidofovir, other antiviral agents; indeed the frequency of renal toxicity decreased from 35% to 29% to 12% in patients who received cidofovir for CMV disease, or for secondary or primary pre-emptive therapy, respectively.

In conclusion, the results of this prospective study indicate that cidofovir may be safely and effectively used as a first choice pre-emptive treatment in HSCT patients, especially in those with a low CMV load according to a PCR assay. Most importantly, early administration of cidofovir as the only antiviral agent is not complicated by renal toxicity. Cidofovir may be delivered in an outpatient setting, being better accepted by the patient and also more cost-effective.

Alberto Bosi, Benedetta Bartolozzi, Alessandro M. Vannucchi, Alessandra Orsi,* Stefano Guidi, Pierluigi Rossi Ferrini
BMT Unit, Department of Hematology; Laboratory of Microbiology, Careggi Hospital, University of Florence, Italy

Key words: cidofovir, CMV, hematopoietic stem cell transplantation, PCR, pre-emptive therapy.

Acknowledgments: supported in part by Fondi MURST ex 60%.

Correspondence: Professor Alberto Bosi, MD, Department of Hematology, BMT Unit, University of Florence, Careggi Hospital, 50134 Florence, Italy. Phone: international +39.055.4277067. Fax: international +39.055.4277064. E-mail: a.bosi@dsf.unifi.it

Acute myeloid leukemia in the elderly: evaluation of overall survival in 69 consecutive patients

The aim of this study was to evaluate the impact of an intensive induction treatment on overall survival in elderly patients (age ≥ 66 years) with acute myeloid leukemia (AML) observed in our institution. Although complete remission was achieved in 58% of treated patients, the median overall survival was equally poor for treated (n=26) and untreated (n=40) patients (5 and 2 months, respectively), raising the question about the usefulness of an aggressive treatment in elderly patients with non-M3 AML.

haematologica 2002; 87:447-448
(http://www.haematologica.as/2002/04/447.htm)

The acute myeloid leukemia in elderly patients is associated with a poor overall survival (OS), regardless of treatment. Possible explanations for this include the frequent evolution from an underlying myelodysplastic syndrome (MDS), a high frequency of unfavourable cytogenetic abnormalities, a poor performance status (PS) and/or the presence of associated diseases contraindicating intensive induction treatment. Cytogenetic abnormalities other than del(5q), MDS and AML were achieved in 58% of treated patients. The median overall survival was equally poor for treated (n=26) and untreated (n=40) patients (5 and 2 months, respectively), raising the question about the usefulness of an aggressive treatment in elderly patients with non-M3 AML.

Manuscript processing
This manuscript was peer-reviewed by two external referees and by Professor Jordi Sierra, Deputy Editor. The final decision to accept this paper for publication was taken jointly by Professor Sierra and the Editors. Manuscript received December 27, 2001; accepted February 19, 2002.

References


Acute myeloid leukemia in elderly patients with non-M3 AML.

haematologica 2002; 87:447-448
(http://www.haematologica.as/2002/04/447.htm)
apy for 1 year (Table 1). The 3 FAB M3 patients (aged 66, 74, and 75 years) received all-trans retinoid acid alone in 1 case and associated with chemotherapy in 2 cases.

The remaining 40 patients (58%; 25 males, 15 females, median age 74 years, range 66-92 years) with organ dysfunction, poor PS (< 60%) or leukemic transformation of MDS (13/40) were excluded from aggressive treatment and received only supportive care (transfusions and/or hydroxyurea).

Among the 26 chemotherapy-treated non-M3 patients, 15 (58%) achieved a CR, 7 (27%) failed to obtain a CR and 4 were not evaluable due to early death. Seven died of treatment-related toxicity (27%; 3/7 while in CR). Eight out of 12 patients who achieved a CR started maintenance therapy but only 2/8 patients could complete the planned treatment, whereas 6/8 relapsed during maintenance therapy. The median OS was 5 months (range 0-114 months), with 2 long survivors (the first patient, with FAB M4 AML and normal karyotype, relapsed after 104 months and the second patient, with FAB M5 AML and trisomy 8, is still in continuous CR after 114 months). On the other hand, the median OS of patients receiving only supportive care was 2 months. Figure 1 reports the survival curves of the two groups of patients. In spite of the statistically significant difference (p = .003), the outcome was equally poor for both groups, the intensive treatment being of benefit in terms of OS only for 2/26 cases (7.7%) and in terms of potential cure only for 1/2. All 3 M3 patients are in continuous CR (after 72, 77 and 84 months), further supporting the concept that M3 AML treated with all-trans retinoid acid-containing regimens is associated with good prognostic perspectives even in the elderly.

In conclusion, in agreement with previous reports, our data do not provide any evidence in favor of intensive treatment for non-M3 AML in the elderly and raise the question of whether an aggressive treatment, although of some benefit for a minority of cases, should ever be applied to this setting of patients. In our opinion, curative treatment should only be considered in elderly patients selected among those with good PS and de novo AML.

Clearly, prospective trials are needed to clarify this point.

Dino Veneri, Flavia Zanetti, Massimo Franchini, Achille Ambrosetti, Giovanni Pizzolo
Dipartimento di Medicina Clinica e Sperimentale, Sezione di Ematologia, Università di Verona, Italy

Correspondence: Prof. Dino Veneri, Dipartimento di Medicina Clinica e Sperimentale, Sezione di Ematologia, Università di Verona, Verona,Italy. E-mail: dino.veneri@univr.it

References


Figure 1. Survival in 40 untreated patients (line A) and in 26 treated patients (line B).